Brief: Adalta Says Co & GPCR Therapeutics Collaborate To Evaluate New Cancer Treatment Approach Combining Beta Blockers Plus Co's CXCR4-Inhibiting I- Bodies

Adalta

13/10/2022 02:28

Oct 13 (Reuters) - Adalta Ltd  1AD.AX :
    * CO & GPCR THERAPEUTICS COLLABORATE TO EVALUATE NEW CANCER
TREATMENT APPROACH COMBINING BETA BLOCKERS PLUS CO'S
CXCR4-INHIBITING I- BODIES

Source text for Eikon:  ID:nASXb8XBXR 
Further company coverage:  1AD.AX 
 ((Reuters.Briefs@thomsonreuters.com;))